转移性肾细胞癌改变血管分布。
Metastatic renal cell carcinoma change vascularity.
作者信息
Azuma Takeshi, Matayoshi Yukihide, Sato Yohsuke, Sato Yujiro, Nagase Yasushi
机构信息
Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-0042, Japan.
出版信息
Case Rep Urol. 2012;2012:654617. doi: 10.1155/2012/654617. Epub 2012 Aug 30.
Abstract
Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of computed tomography. To our knowledge, this is the first report that tumor's character change induced by molecular targeted agents can be detected and the efficacy of molecular targeted agents can be predicted.
摘要
几种分子靶向药物已被批准用于转移性肾细胞癌（mRCC）的临床治疗。本文报道了一例32岁的mRCC女性患者。这些肿瘤可通过分子药物的给药改变血管生成情况。我们可以根据计算机断层扫描的结果及时选择药物。据我们所知，这是第一份关于可检测到分子靶向药物引起的肿瘤特征变化并能预测分子靶向药物疗效的报告。
相似文献
1
Metastatic renal cell carcinoma change vascularity.转移性肾细胞癌改变血管分布。
Case Rep Urol. 2012;2012:654617. doi: 10.1155/2012/654617. Epub 2012 Aug 30.
2
Comprehensive managements of metastatic renal tumor with Mayo III inferior vena cava tumor thrombus: a case report.梅奥III级下腔静脉瘤栓转移性肾肿瘤的综合管理：一例报告
Transl Androl Urol. 2020 Apr;9(2):812-818. doi: 10.21037/tau.2019.12.13.
3
Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.原发灶不明的癌（CUP）合并转移性肾细胞癌（mRCC）组织学和免疫组织化学特征（CUP-mRCC）：接受靶向治疗的连续患者的结果和文献复习。
Clin Genitourin Cancer. 2019 Feb;17(1):e32-e37. doi: 10.1016/j.clgc.2018.08.005. Epub 2018 Aug 28.
4
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.血管内皮生长因子靶向治疗转移性肾细胞癌患者相关毒性治疗中止的风险因素和预测模型：来自国际转移性肾细胞癌数据库联盟的结果。
Cancer. 2016 Feb 1;122(3):411-9. doi: 10.1002/cncr.29773. Epub 2015 Nov 5.
5
Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction.分子靶向药物在肾功能障碍的转移性肾细胞癌患者中的安全性和疗效。
Anticancer Drugs. 2011 Sep;22(8):794-800. doi: 10.1097/CAD.0b013e328346af0d.
6
Clinical analysis of everolimus in the treatment of metastatic renal cell carcinoma.依维莫司治疗转移性肾细胞癌的临床分析
Ann Palliat Med. 2021 Jan;10(1):584-589. doi: 10.21037/apm-20-2465. Epub 2021 Jan 18.
7
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.分子亚型提高国际转移性肾细胞癌数据库联盟预后模型的预后价值。
Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.
8
The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.靶向治疗时代转移性肾细胞癌患者的医疗机构病例数量与总生存期之间的关联。
Urol Oncol. 2018 Oct;36(10):470.e19-470.e29. doi: 10.1016/j.urolonc.2018.06.013. Epub 2018 Aug 18.
9
Sonography monitoring of thyroid morphology and function in patients with metastatic renal cell carcinoma treated with targeted drugs.靶向药物治疗转移性肾细胞癌患者的甲状腺形态和功能的超声监测。
Ann Palliat Med. 2020 Jul;9(4):1577-1585. doi: 10.21037/apm-19-524. Epub 2020 Jul 14.
10
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.细胞减灭性肾切除术治疗肾细胞癌同步转移患者：来自国际转移性肾细胞癌数据库联盟的结果。
Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.
本文引用的文献
1
Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.最大限度延长转移性肾细胞癌患者的疾病控制时间：专家共识。
Med Oncol. 2012 Sep;29(3):1896-907. doi: 10.1007/s12032-011-0016-8. Epub 2011 Jul 7.
2
Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.使用mTOR抑制剂再次挑战转移性肾细胞癌的疗效。
Acta Oncol. 2011 Oct;50(7):1135-6. doi: 10.3109/0284186X.2011.592149. Epub 2011 Jul 5.
3
Sunitinib rechallenge in metastatic renal cell carcinoma patients.舒尼替尼二线治疗转移性肾细胞癌。
Cancer. 2010 Dec 1;116(23):5400-6. doi: 10.1002/cncr.25583. Epub 2010 Nov 2.
4
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.血管内皮生长因子受体和血小板衍生生长因子受体多靶点抑制剂SU11248在转移性肾细胞癌患者中的活性
J Clin Oncol. 2006 Jan 1;24(1):16-24. doi: 10.1200/JCO.2005.02.2574. Epub 2005 Dec 5.
5
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.多剂量水平的新型雷帕霉素激酶抑制剂哺乳动物靶点CCI-779用于晚期难治性肾细胞癌患者的随机II期研究。
J Clin Oncol. 2004 Mar 1;22(5):909-18. doi: 10.1200/JCO.2004.08.185.
Zotero 插件